3,3-Dichloro-cyclopropane-1,2-dicarboxylic acid | 69405-97-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3,3-Dichloro-cyclopropane-1,2-dicarboxylic acid
• 英文别名: 3,3-Dichloro-1,2-cyclopropanedicarboxylic acid；3,3-dichlorocyclopropane-1,2-dicarboxylic acid
• CAS: 69405-97-6
• 化学式: C₅H₄Cl₂O₄
• mdl: MFCD00180925
• 分子量: 198.99
• InChiKey: RPCDSJZGXPPDGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Therapeutic compounds for treating dyslipidemic conditions
  申请人：——

  公开号：US20040266849A1

  公开（公告）日：2004-12-30

  The present invention relates to novel LXR ligands of Formula (I) and the pharmaceutically acceptable salts and esters thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol. 1

  本发明涉及公式（I）的新型LXR配体及其药学上可接受的盐和酯，其对治疗脂质代谢异常，特别是低水平的高密度脂蛋白胆固醇具有用处。
• Methods and compositions to promote bone homestasis
  申请人：Van Rompaey Luc

  公开号：US20060020036A1

  公开（公告）日：2006-01-26

  The present invention relates to a method for promoting osteogenesis by contacting osteoblast progenitor cells with an LXR agonist. Said method is useful for the treatment or prevention of an imbalance in bone homeostasis in a subject using bone homeostasis-promoting compositions comprising an effective osteogenic stimulating amount of an LXR agonist in admixture with a pharmaceutically acceptable carrier. A further aspect is a method to produce bone tissue in vitro by contacting an LXR agonist with a population of osteoblast progenitor cells on a substrate, for a time sufficient to stimulate the generation of a matrix of bone tissue.

  本发明涉及一种通过使成骨细胞祖细胞与 LXR 激动剂接触来促进成骨的方法。所述方法可用于使用骨平衡促进组合物治疗或预防受试者骨平衡失调，该组合物包含有效成骨刺激量的 LXR 激动剂，并与药学上可接受的载体混合。另一个方面是一种体外生成骨组织的方法，其方法是将 LXR 激动剂与基质上的成骨祖细胞群接触，接触时间足以刺激骨组织基质的生成。
• THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS
  申请人：Merck & Co., Inc.

  公开号：EP1458694A2

  公开（公告）日：2004-09-22
• EP1458694A4
  申请人：——

  公开号：EP1458694A4

  公开（公告）日：2005-12-14
• [EN] THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS<br/>[FR] COMPOSES THERAPEUTIQUES DESTINES AU TRAITEMENT D'ETATS DYSLIPIDEMIQUES
  申请人：MERCK & CO INC

  公开号：WO2003053352A2

  公开（公告）日：2003-07-03

  The present invention relates to novel LXR ligands of Formula (I) and the pharmaceutically acceptable salts and esters thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.